Mirum Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on May 4, 2026, by Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM). The filing reports a material event under Item 8.01: the announcement that the primary endpoint was met in the VISTAS Phase 2b clinical study evaluating volixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC).
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial results and regulatory timelines.
Material Changes and Clinical Results
The VISTAS Phase 2b study included 158 patients with PSC. The primary analysis cohort (n=111) consisted of patients with moderate to severe itch. Key efficacy results for the primary analysis cohort (Volixibat 20 mg BID vs. Placebo) include:
- Primary Endpoint: Volixibat demonstrated a robust 2.72 point improvement in pruritus (Adult ItchRO scale) versus a 1.08 point improvement for placebo, resulting in a placebo-adjusted difference of 1.64 points (p<0.0001).
- Responder Rate: 55.6% of volixibat-treated patients achieved a ≥2 point reduction in Adult ItchRO compared to 26.3% in the placebo group (p=0.0019).
- Biomarker: Statistically significant reduction in serum bile acids (sBA) was observed (-33.7 vs. 2.1, p=0.0324).
- Onset: Statistically significant improvements were observed within two weeks of treatment.
Safety Profile: The safety profile was consistent with known IBAT inhibition effects. Treatment-emergent adverse events (TEAEs) occurred in 93.5% of volixibat patients vs. 84.0% of placebo patients. Common TEAEs (≥5%) included diarrhea (40.3% vs. 8.6%), abdominal pain (18.2% vs. 9.9%), and nausea (13.0% vs. 3.7%). Elevations in liver enzymes (ALT, AST, ALP) and bilirubin were observed more frequently in the volixibat group.
Guidance, Outlook, and Risks
Regulatory Timeline:
- Pre-NDA Meeting: Scheduled with the U.S. FDA for summer 2026.
- NDA Submission: Planned for the second half of 2026.
- Data Presentation: Full results to be presented at the European Association for the Study of the Liver International Liver Congress on May 30, 2026.
Other Pipeline Updates: The Company now expects topline data from the VANTAGE Phase 2b study of volixibat in primary biliary cholangitis (PBC) in the first quarter of 2027.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include uncertainties in regulatory approval, the success of the NDA submission, and the inherent risks of pharmaceutical R&D. The Company notes that actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the statistical significance and clinical relevance of the 1.64 point placebo-adjusted difference in the Adult ItchRO scale.
- Confirm the safety monitoring plan for liver enzyme elevations (ALT, bilirubin) given the higher frequency in the treatment arm.
- Monitor the outcome of the pre-NDA meeting scheduled for summer 2026 to validate the H2 2026 submission timeline.
- Review the full data presentation at the International Liver Congress on May 30, 2026, for detailed subgroup analyses.
- Track the timeline for the VANTAGE Phase 2b study in PBC, now expected in Q1 2027.